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Effects of acute pre-treatment 
with ethanolamine on isoprenaline-
induced myocardial infarction in 
adult Wistar rats
EFFECTS OF 
ETHANOLAMINE 
ON MYOCARDIAL 
INFARCTION
24 hours.(16,17) The current study investigated whether Etn can 
protect the heart in an in vivo model of ischaemic injury. 
METHODS
Animals
Adult male Wistar rats (250 - 300g) were obtained from the 
University of Cape Town Animal Unit and allowed to acclima-
tise for 2 days under standard laboratory conditions (12 hour 
light/dark cycle 06h00 - 18h00, 300 lux, 22 ± 1°C) prior to 
experiments. Rats were fed standard rat chow (Afresh Ven-
tion 1, RSA) and had ad libitum access to food and water. 
Experiments were approved by the Faculty of Health Sciences 
Animal Ethics Committee at the University of Cape Town 
and performed in compliance with the Guide for the Care and 
Use of Laboratory Animals (NIH Publication No.85 (23), 
revised 1996). 
Experimental Design
Rats (n=53) were divided into 2 groups: Control and ISO. 
The ISO group were treated with a single dose of ISO 
ABSTRACT
Ethanolamine (Etn), a biogenic amine, protects isolated 
hearts against MI, but its effects in vivo are unknown. 
In this study, we investigated the effects of Etn pre-
treatment on isoprenaline (ISO)-induced MI in vivo. 
Wistar rats were treated with either Etn (10mg.kg-1, 
i.p.) or saline, prior to either ISO (67mg.kg-1, s.c.) or 
saline. Haemodynamic- and electrocardiographic para-
meters were recorded under anaesthesia, 24 hours 
post-treatment with ISO. Infarct sizes were determined 
by triphenyltetrazolium chloride staining. Oxidative 
stress plasma parameters, conjugated dienes (CD) 
and thio-barbituric acid reactive substances (TBARS), 
were measured by spectrophotometric analysis. Etn 
decreased ISO-induced pathological Q-waves, but had 
no effect on ISO-induced low-voltage electrocardio-
gram. In addition, Etn decreased overall mortality 
induced by ISO treatment. However, Etn did not pre-
vent ISO-induced infarction or the systolic- and diastolic 
hypotensive effects. Etn also enhanced the ISO-induced 
increase in heart-to-body weight ratio, and reversed 
the decrease in lungs-to-body weight ratio. Neither ISO 
nor Etn altered CD or TBARS. These results suggest 
that, despite a tendency to modulate cardiac electrical 
activity, Etn did not prevent ISO-induced MI or myo-
cardial dysfunction in vivo.  SAHeart 2016;13:112-118
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INTRODUCTION
Ethanolamine (Etn) is a biogenic amine that plays an important 
role in mediating cellular growth and chemical signalling pro-
cesses.(1,2) In animals, Etn is found both as a component of 
membrane phospholipids and as a freely circulating organic 
compound in the blood. Consistent with its metabolic functions, 
the plasma levels of Etn vary with age and requirement for 
growth, with infants having much higher plasma concentrations 
of Etn than adults.(3) Etn also exists naturally in many types of 
food, including those known to modulate cardiovascular tissue 
survival such as wine,(4,5) grapes(6) and chocolate.(7) 
Physiologically, Etn has been implicated in regulation of cellu-
lar activity in cardiovascular and other tissues. In isolated 
fibroblasts,(8) and isolated hepatocytes,(9) Etn has co-mitogenic 
effects. It has also been shown to increase hepatocyte pro-
liferation in regenerating livers in vivo.(10) In the cardiovascular 
system, chronic Etn treatment in rats is associated with attenu-
ation of hypercholesterolemia.(11) Furthermore, both chronic(12) 
and acute(13) pre-treatment with Etn protect the isolated rat 
heart from ischaemia-reperfusion injury. Despite these cardio-
protective effects in isolated hearts, the effects of Etn on in vivo 
myocardial infarction (MI) are currently unknown. 
Acute MI induced by the catecholamine isoprenaline (ISO), 
a synthetic analogue of epinephrine, results in infarct-like 
lesions similar to those found during human MI.(14,15) High-
dose ISO induces MI-associated pathology in this model after 
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(67mg.kg-1, s.c.) to induce MI.(17) The Control group received 
equivalent volumes of 0.9% saline (3.3ml.kg-1, s.c). These 2 
groups were further subdivided into Etn and vehicle treated 
groups (Figure 1) as follows: Control + Vehicle, Control + Etn, 
ISO + Vehicle, and ISO + Etn. Etn-treated rats were injected 
with Etn (10mg.kg-1, i.p.) 2 hours prior to induction of MI. 
Vehicle-treated groups received equivalent volumes of saline 2 
hours prior to induction of MI. A dose-response was established 
to determine the optimal dose and timing of Etn administration 
and a therapeutic dose of 10mg.kg-1 of Etn was selected based 
on the ability to modulate MI-induced ECG disruptions.
In vivo electrophysiological, haemodynamic and gross 
structural measurements
Of the 53 rats used in this study, 6 rats died within 24 hours of 
ISO treatment, without Etn pre-treatment and 1 died with Etn 
pre-treatment prior to induction of MI by ISO. The 7 rats 
that died were excluded from further analyses. The surviving 
rats (n=46) were anaesthetised with sodium pentobarbitone 
(60mg.kg-1, i.p.) 24 hours after induction of MI. Rats were 
intubated and ventilated at a rate of 70 strokes.min-1 (2.5ml 
room air.stroke-1) on a rodent ventilator (Model 681, Harvard 
Apparatus, USA). Body temperature, monitored using a rectal 
probe, was maintained at 37°C using a heating pad. The depth 
of anaesthesia was assessed using the pedal withdrawal reflex 
and, when required, a top-up dose of pentobarbitone (12mg.
kg-1, i.p.) was given. Heart rate was monitored from lead II of a 
3-lead surface electrocardiogram (ECG) connected to the 
PowerLab system via an Animal Bio Amplifier (ML136, 
ADInstruments, Aus). Arterial blood pressure was measured in 
the right carotid artery using a heparinised, custom-made 
cannula attached to a pressure transducer (MLT0670, Lasec, 
RSA). Blood pressure readings were recorded by the PowerLab 
system via a Bridge Amplifier (ML221, ADInstruments, Aus). All 
electrophysiological and haemodynamic data recorded online 
by the PowerLab system were digitally acquired and analysed 
using the LabChart Pro 7 software (ADInstruments, Australia). 
After the recordings, a thoracotomy was performed and the 
heart was rapidly excised, flushed with cold saline (4°C) via the 
aorta, weighed, and stored at -20°C for staining. 
Quantifi cation of infarct size
Frozen hearts were cut transversely into 2mm slices from apex 
to base of the ventricles using a custom made Perspex mould 
and a stainless steel blade. The uppermost slice, consisting of 
the atria, was discarded. The slices were incubated in 1% 
sodium phosphate buffered triphenyltetrazolium chloride 
(TTC) solution (pH7.4) for 20min at 37°C and subsequently 
stored in 10% formalin solution at room temperature. After 
24 hours, slices were placed on glass slides and digitally scanned. 
Infarct size was measured as the region of interest using ImageJ 
software (Version 1.44p, National Institute of Health, USA). 
Infarct size was quantified as the percentage of TTC-negative 
area to total ventricular area.
Quantifi cation of organ weight to body weight ratio
The heart, lungs, kidneys, liver and adrenal glands were removed 
at the time of thoracotomy. Each organ was blotted dry of any 
external blood and weighed. The organ weight was expressed 
as a percentage of the starting body weight (i.e. the weight 
before any drug treatments) for each rat.
Lipid peroxidation assays
The concentration of conjugated dienes (CD) was determined 
using the assay described by Esterbauer, et al.(18) Briefly, 100μL 
of plasma was added to 405μL chloroform:methanol (2:1). 
After centrifugation at 6 000g for 15min, the top aqueous layer 
was removed and the organic layer was isolated and dried 
under nitrogen. Cyclohexane (0.25ml) was added to solubilise 
the dry organic residue and the absorbance was read at 
234nm on a spectrophotometer (Multiscan MS analyser, AEC 
Amersham, RSA). A molar extinction coefficient of 2.95x04/M/
cm was used. 
Thiobarbituric acid reactive substances (TBARS) were meas-
ured using the method described by Jentzsch, et al.(19) Briefly, to 
50μL of plasma samples was added 6.25μL of 4mmol/L Etn: Ethanolamine, MI: Myocardial infarction.
FIGURE 1: Timeline of treatments and measurements. 
Physiological measurements included ECG and arterial blood 
pressure. 
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butylated hydroxytoluene/ethanol and 50μL of 0.2M ortho-
phosphoric acid. The samples were then vortexed. TBA reagent 
(6.25μL), at 0.11mol/L in 0.1mol/L NaOH, was added and the 
mixture was microfuged at 3 000g for 2min to collect small 
volumes at the bottom of the Eppendorfs. The volumes were 
heated at 90°C for 45min, then placed on ice for 2min and then 
at room temperature for 5min before n-butanol (500μL) was 
added. Phase separation was enhanced by the addition of 
50μL of saturated NaCl. The samples were vortexed and 
centrifuged at 12 000g for 2 min and 300μL of the top butanol 
phase was transferred into wells and read at A532nm on a 
spectrophotometer (Multiscan MS analyser, AEC Amersham, 
RSA). A molar extinction coefficient of 1.54x105/M/cm was 
used. CD and TBARS measurements were performed in trip-
licate and the mean value was taken as the final result.
Drugs and chemicals
Sodium pentobarbitone was purchased from Kyron Laboratories 
(Johannesburg, RSA). Other drugs and chemicals were obtained 
from Sigma-Aldrich (Johannesburg, RSA).
Statistical analysis
All data are expressed as mean ± standard error of the mean 
(SEM). Column statistics were conducted to check if data 
passed normal distribution with the D’Agostino and Pearson 
normality test. For normally distributed data, comparisons 
between groups were performed using a one-way ANOVA 
(Prism 5, Graphpad, USA) followed by a Tukey post-hoc test 
to compare group means. For data that was not normally 
distributed, a Kruskal-Wallis test was used for comparisons 
between groups, followed by a Dunns post-hoc test. A value of 
p<0.05 was considered statistically significant.
RESULTS
Reduction of isoprenaline-induced mortality by acute 
pre-treatment with ethanolamine
Six of the 20 rats that were injected with ISO following a saline 
injection died, whereas only one of the 14 rats that were 
injected with ISO following Etn pre-treatment died. Therefore, 
mortality was reduced by 22.9% when rats, subjected to ISO-
induced MI, were pre-treated with an acute dose of Etn.
Haemodynamic parameters are not improved by acute 
pre-treatment with ethanolamine
The administration of ISO caused arterial hypotension 
(Figure 2) as evidenced by a significant decrease in the systolic 
(Control: 147.7 ± 4.9mmHg, ISO: 116.8 ± 3.3mmHg; p<0.001) 
and diastolic (Control: 119.5 ± 3.5mmHg, ISO: 93.9 ± 
4.1mmHg; p<0.01) arterial blood pressure, compared to 
Control rats. Arterial hypotension of a similar magnitude was 
seen in rats treated with ISO + Etn (systolic: 113.2 ± 4.6mmHg; 
diastolic: 87.6 ± 4.9mmHg; p<0.001 vs. Control).
Ethanolamine improves some, but not all, electrophys-
iological disturbances 
The average lead II ECG tracings in the different treatment 
groups can be seen in Figure 3 and Table I summarises the 
quantification of the ECG data for each treatment. The heart 
rate, PR-interval, QRS-interval, QT-interval and P-duration 
were unaffected by ISO or Etn treatment. When the QT-
interval was corrected for heart rate (QTc) using the Bazett’s 
formula, it was found that treatment with ISO + Etn resulted in 
a decreased QTc compared to control rats (p<0.05 vs. 
Control), although this change was not observed in rats treated 
with ISO alone. There was no significant difference in QTc 
between ISO and ISO + Etn treated rats. 
n≥6 **p<0.01, ***p<0.001 (Treatment vs. Control).
FIGURE 2: The effects of isoprenaline and ethanolamine on arterial blood pressure. A: systolic-, and B: diastolic pressures. 
Isoprenaline caused arterial hypotension and pre-treatment with ethanolamine did not improve this condition. 
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In general, ISO-treated rats produced low-voltage ECG 
recordings as seen by decreased amplitudes of the R- and 
T-waves (p<0.001 vs. Control). Pre-treatment with Etn in ISO-
treated rats did not restore either of these parameters to 
control values. ISO also induced pathologically large Q-waves 
(p<0.01 vs. Control), an effect consistent with an evolving MI. 
Rats treated with ISO + Etn exhibited Q-waves that were not 
significantly different from those in Control rats. ISO treatment 
caused a shortening of the Tpeak-Tend parameter (p<0.05 vs. 
Control). Treatment with ISO + Etn caused a further shortening 
of the Tpeak-Tend (p<0.001 vs. Control). 
Infarct size is not affected by acute pre-treatment with 
ethanolamine 
Infarct size was determined in all hearts using TTC staining 
(Figure 4). The myocardium of the Control hearts was positive 
for TTC (dark red colour), whereas in ISO treated groups the 
intensity of TTC staining was decreased, indicating the pre-
sence of a global infarction. ISO administration significantly 
increased the infarct size compared to Control rats (14.7 ± 
1.9% vs. 5.7 ± 0.6%, p<0.01). Hearts in the ISO + Etn group 
also had a significantly greater infarct size compared to Control 
(13.5 ± 5.3%, p<0.01). There was no significant difference 
between the infarct size of rats treated with ISO alone and 
those treated with ISO + Etn. Administration of Etn alone had 
no significant effect on infarct size compared to Control (5.8 ± 
1.0%, p=n.s. vs. Control). 
TABLE 1: Summary of ECG characteristics for the effects of 
ethanolamine on myocardial infarction.
*p<0.05, **p<0.01, ***p<0.001 (Treatment vs. Control), n≥6.
 Control ISO ISO + Etn Etn
Heart Rate 403.7 ± 12.4 405.8 ± 10.9 398.5 ± 7.7 394.1 ± 10.6
(beats.min-1)
QT-Interval (s) 0.055 ± 0.001 0.049 ± 0.005 0.044 ± 0.005 0.056 ± 0.001
QTc (s) 0.146 ± 0.002 0.128 ± 0.014 0.100 ±0.010* 0.143 ± 0.004
Tpeak-Tend (s) 0.030 ± 0.0 0.022 ± 0.002
* 0.016 ± 0.002*** 0.030 ± 0.0
Q-Amplitudex -0.032 ± 0.008 -0.130 ± 0.027** -0.093 ± 0.017 -0.018 ± 0.011
(mV)
R-Amplitude  0.648 ± 0.036 0.167 ± 0.013*** 0.225 ± 0.029*** 0.588 ± 0.054
(mV)
T-Amplitude  0.158 ± 0.014 0.044 ± 0.016*** 0.054 ± 0.017** 0.120 ± 0.013
(mV)
Orange lines are the average tracing for Control: n=12 rats, ISO: n=14 rats, ISO + Etn: n=13 rats and Etn: n=7 rats. Grey lines indicate traces from individual rats. 
FIGURE 3: The effects of isoprenaline and ethanolamine on electrical activity. Superimposed original lead II ECG tracings from all 
4 treatment groups. 
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Heart weight to body weight ratio is increased by acute 
pre-treatment with ethanolamine
Hearts were weighed immediately after flushing with saline and 
their weight was expressed as a percentage of the initial 
body weight of the rat (Figure 5). Rats treated with ISO 
displayed an increased heart weight to body weight (HW/BW) 
ratio (4.8 ± 0.2mg.g-1, p<0.0001) compared to saline-treated 
rats (3.3 ± 0.1mg.g-1). Pre-treatment with Etn further increased 
this change (5.1 ± 0.2mg.g-1, p<0.0001 vs. Control; p<0.05 vs. 
ISO alone). Treatment with Etn alone did not affect the HW/
BW ratio (3.3 ± 0.0mg.g-1, p=n.s. vs. Control). 
Isoprenaline and ethanolamine do not affect lipid 
peroxidation
Treatment with ISO caused no significant difference in the 
quantity of CDs in the plasma (p=n.s. vs. saline; Table II). Similar 
results were seen when rats were treated with ISO + Etn. The 
quantities of TBARS were also not significantly altered by ISO 
or ISO + Etn administration compared to saline-treated rats. 
Treatment with Etn alone had no significant effect on the 
concentration of CDs or TBARS produced.
Effects of isoprenaline and ethanolamine on non-cardiac 
structures
ISO caused a 3.52% loss in body weight compared to Control 
(p<0.01) and treatment with ISO + Etn resulted in a further 
loss in body weight by 2.05% (p<0.001 vs. Control, Table III). 
ISO + Etn appeared to protect against the ISO-induced 
decrease in the lungs/BW ratio (Table III). ISO neither affected 
the gross structural appearance of the liver, kidneys and the 
adrenal glands nor impacted the weight of these organs.
DISCUSSION
In this study, we demonstrated that pre-treatment with Etn 
(10mg.kg-1) given 2 hours prior to induction of MI does not 
n≥6 **p<0.001 vs. Control.
FIGURE 4: The effect of ethanolamine on isoprenaline-
induced MI. A: Representative cross sections of ventricular 
myocardium from each group stained with TTC. B: Infarct size 
expressed as a percentage of total ventricular area.
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FIGURE 5: Changes in heart weight to body weight 
(HW/BW) ratio. 
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TABLE 1I: The effects of isoprenaline and ethanolamine on the 
products of lipid peroxidation.
p=n.s., n≥6.
 Control ISO ISO + Etn Etn
CD (μmol/L) 45.8 ± 5.1 60.3 ± 2.4 55.3 ± 6.4 44.9 ± 8.4
TBARS (μmol/L) 4.16 ± 0.20 4.12 ± 0.20 3.90 ± 0.56 4.88 ± 1.03
TABLE III: Alterations in body weight (BW) and organ weights 
in Control, isoprenaline and ethanolamine treated rats.
**p<0.01, ***p<0.01 (Treatment vs. Control), n≥6.
 Control ISO ISO + Etn Etn
BW Lost (%) -0.01 ± 1.8 -3.53 ± 2.1** -5.58 ± 3.2*** -0.62 ± 1.4
Liver/BW Ratio 50.59 ± 1.40 45.73 ± 1.41 46.74 ± 1.06 48.95 ± 1.49
Lungs/BW Ratio 7.33 ± 0.12 6.44 ± 0.09** 6.93 ± 0.19 7.14 ± 0.42
Kidneys/BW Ratio 10.73 ± 0.12 10.29 ± 0.14 10.44 ± 0.11 10.9 ±0.31
Adrenals/BW Ratio 0.37 ± 0.01 0.39 ± 0.01 0.42 ± 0.02 0.36 ± 0.03
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decrease the infarction caused by ISO but does reduce ISO-
induced mortality, although significantly increasing the HW/BW 
ratio. Furthermore, there were significant changes in electro-
cardiographic parameters in ISO + Etn treated hearts compared 
to Control hearts, which were not seen in hearts treated with 
ISO alone. Incidentally, ISO + Etn pre-treatment reversed the 
ISO-induced decrease in lungs/BW ratio. 
ISO caused severe disruption to the electrical activity of the 
heart after 24 hours. ISO administration produced low voltage 
R-waves. The R-wave characterises ventricular depolarisation 
and abnormalities may represent myocardial oedema and poor 
R-wave progression (PRWP), which is indicative of an anterior 
MI.(20) Treatment with Etn did not restore R-wave values. ISO 
also induced pathologically large Q-waves which is an effect 
consistent with an evolving MI. Pre-treatment with Etn restored 
the Q-wave value near to control levels, which may have 
positively altered the evolution of the MI. ISO also affected the 
Tpeak-Tend parameter which provides an indication of transmural 
dispersion of repolarisation.(21) Treatment with Etn appeared to 
worsen this parameter, suggesting that Etn may have altered 
the architecture of the myocardium. This suggestion is 
supported by the increased HW/BW ratio induced in the 
ISO + Etn group. The amplitude of the T-wave was decreased 
when ISO was administered and was not improved with Etn 
pre-treatment. This may be indicative of disturbances in 
electrolyte balance, left ventricular hypertrophy or left bundle 
branch block.(22) Pre-treatment with Etn caused a shortening of 
the QTc compared to control rats, an alteration that was not 
viewed in ISO-only treated rats.  
Despite some of the modulations on electrical activity 
mentioned above, in the current study pre-treatment with Etn 
failed to affect the infarct size in an ISO-induced model of MI 
in vivo. In contrast, Etn pre-treatment has previously been 
shown to decrease infarct size in a Langendorff perfused 
model of ischaemia-reperfusion injury.(13) The possible reasons 
for these differences include large variations in infarct size seen 
in the groups treated with ISO, suggesting that individual rats 
responded differently to ISO and therefore the infarct was 
not reproducible. In addition, the dose (10mg.kg-1) and time 
(2 hours prior to ISO) of administration of the drug may not 
have been optimal since the global nature of the infarct in this 
study was different from regional infarcts induced in isolated 
hearts. If the dose of Etn administered in this study remained in 
the blood, it would amount to a concentration of 3μM (working 
on a blood volume of 64ml.kg-1), which may not have been 
sufficient to elevate the plasma concentration of Etn above its 
physiological levels of approximately 30μM.(3) Furthermore, it is 
unlikely that the Etn remained in the blood since it is often 
incorporated into phospholipid membranes.(23) 
ISO causes cardiac-specific dysfunction, being a synthetic 
catecholamine that targets ß-adrenergic receptors in the heart; 
however ISO also affects other organs.(14,24) In this study we 
found that ISO caused a decrease in the lungs/BW ratio. The 
effect of ISO on lungs/BW ratio has not been extensively 
researched however, being a ß-adrenergic agonist, ISO can 
increase Na+ active transport, which may cause fluid clearance 
in the lungs.(25,26) This may explain the decrease in the lungs/BW 
ratio after 24 hours. Pre-treatment with Etn prevented the ISO-
induced decrease in lungs/BW ratio which may suggest an 
interaction of Etn with Na+ active transport. 
The increased HW/BW ratio could be indicative of hypertrophy 
and/or oedema, fibroblast proliferation and infiltration of inflam-
matory cells. Etn has not previously been linked to oedema, 
however it is possible that Etn could exacerbate hypertrophy 
and fibroblast proliferation in a damaged organ, particularly as 
Etn has been shown to act as a co-mitogen(8,27,28)  and several 
mitogens are upregulated and/or released in response to MI, for 
example; myostatin,(29) vascular endothelial growth factor(30) and 
hepatocyte growth factor.(31,32) Furthermore, Etn induced 
cardioprotection in isolated hearts is mediated by STAT-3 
activation.(13) The JAK/STAT pathway plays a pivotal role in the 
development of cardiac hypertrophy.(33) The fact that Etn alone 
did not affect HW/BW ratio suggests that it is unlikely that 
administration of Etn in vivo, in an undamaged heart, may have 
interacted with STAT-3 to cause hypertrophy. However, the 
increase in HW/BW ratio seen in the ISO + Etn group may 
suggest that stimulation of STAT-3 by Etn in an already damaged 
heart, or some drug-drug interaction between ISO and Etn, may 
facilitate structural alterations of the heart. 
Contrary to several previous studies, our data suggest that 
ISO did not increase oxidative stress. Karthikeyan, et al.,(34) Patel, 
et al.,(35) and Mukherjee, et al.(36) reported that ISO causes an 
increase in oxidative stress markers. However, there were 
several critical differences between these studies and the 
current study: (1) animals in the previous studies received 
repeated doses of ISO, as compared to the single dose 
administered in the current study, (2) measures of lipid 
peroxidation and oxidative stress were measured two or more 
days after the initial dose of ISO, as compared to 24 hours after 
the initial dose in the current study, (3) all 3 of these studies 
analysed homogenised myocardium, not circulating plasma. 
Interestingly, in support of our findings Röth, et al.(37) demon-
strated that although tissue levels of TBARS were elevated 
after cardiac injury induced by coronary artery ligation, they 
had returned to basal levels by 24 hours after ISO administra-
tion. Future studies should include an analysis of the effects of 
ethanolamine on tissue levels of lipid peroxidation indicators in 
ISO induced MI. Furthermore, bearing in mind that the signalling 
pathways involved in the global MI induced by ISO may not be 
the same as those involved in the regional MI, repetition of this 
study in a model of coronary artery ligation may provide further 
insights into the protective nature of Etn.
In conclusion, we have shown that Etn pre-treatment minimises 
ISO-induced mortality, but does not directly reverse the co-
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induced global MI. The mechanisms by which this improved 
survival occurs have not been identified in this study and require 
further investigation. Despite the lack of protection against MI, 
Etn still potentially modulates the heart, possibly via architectural 
changes in the heart as shown by diminished ECG disruptions 
and increased HW/BW ratio.  
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